BNP Paribas Exane analyst Navann Ty raised the firm’s price target on Phibro Animal Health (PAHC) to $37 from $24 and keeps a Neutral rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC:
- Phibro Animal Health Corp’s Earnings Call Highlights Robust Growth
- Phibro Animal Health Faces AI-Driven Risks Threatening Business Stability
- Phibro Animal Health price target raised to $27 from $19 at BofA
- Phibro Animal Health Reports Strong Fiscal Year Results
- Phibro Animal Health: Strong Q4 Results and Strategic Growth Initiatives Tempered by Valuation Concerns Leading to Hold Rating